Adverse events (preferred term)
Omalizumab powder for solution (n= 81)n (%)
Omalizumab solution (n= 74)n (%)
Total (n= 155) n (%)
Headache
21 (25.9)
16 (21.6)
37 (23.9)
Sinus congestion
6 (7.4)
7 (9.5)
13 (8.4)
Rhinorrhoea
4 (4.9)
7 (9.5)
11 (7.1)
Pharyngolaryngeal pain
8 (9.9)
3 (4.1)
11 (7.1)
Sneezing
5 (6.2)
3 (4.1)
8 (5.2)
Nausea
5 (6.2)
3 (4.1)
8 (5.2)
Nasal congestion
3 (3.7)
4 (5.4)
7 (4.5)
Vomiting
3 (3.7)
2 (2.7)
5 (3.2)
Arthralgia
4 (4.9)
1 (1.4)
5 (3.2)
Nasopharyngitis
1 (1.2)
4 (5.4)
5 (3.2)
Table 5:
Most commonly reported adverse events (>4 subjects in the overall study population).
Goto home»
